Candel Therapeutics Grants 25,000 Stock Options to New Employee

Candel Therapeutics announced that its Compensation Committee granted stock options to one new employee on June 30, 2026. The grant includes options to purchase an aggregate of 25,000 shares of common stock at an exercise price of $10.30 per share. These inducement awards, made under the Company's 2025 Inducement Plan, vest 25% on the first anniversary and the remaining 75% in 36 equal monthly installments, subject to continued employment. Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies for cancer.